Associations - EGFR A763_Y764insFQEA

EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	gefitinib Sensitive: C3 – Early Trials	gefitinib Sensitive: C3 – Early Trials
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	osimertinib Sensitive: C3 – Early Trials	osimertinib Sensitive: C3 – Early Trials
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	afatinib Sensitive: C3 – Early Trials	afatinib Sensitive: C3 – Early Trials
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Cancer Lung Cancer	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C4 – Case Studies	erlotinib Sensitive: C4 – Case Studies
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies	Tyrosine kinase inhibitor Sensitive: C4 – Case Studies
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	osimertinib Sensitive: D – Preclinical	osimertinib Sensitive: D – Preclinical
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Lung Adenocarcinoma LUAD	erlotinib Sensitive: D – Preclinical	erlotinib Sensitive: D – Preclinical
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: D – Preclinical	afatinib Sensitive: D – Preclinical
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: D – Preclinical	dacomitinib Sensitive: D – Preclinical
EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	EGFR A763_Y764insFQEA EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: D – Preclinical	osimertinib Sensitive: D – Preclinical